Arun R Shrivats

About Me

I bring a decade of healthcare product experience built on a foundation in genome editing bench research. At Exact Sciences, I've combined product, strategy, operations, and partnerships in the pursuit of eradicating cancer.

Today, I lead a $700M global early-stage cancer diagnostics business. My portfolio spans Oncotype DX, Riskguard hereditary cancer testing, AI-powered digital pathology products, and a multi-product portfolio platform serving oncologists, surgeons, pathologists, and genetic counselors. I lead cross-functional initiatives across R&D, clinical, medical, operations, marketing, training, and sales to bring cancer diagnostics to market at scale. Previously, I led Exact's Corporate Strategy team focused on the Oncology and International businesses.

Prior to Exact, I spent ~5 years as a strategic partner to pharma, biotech, diagnostics, and tools organizations, first at L.E.K. Consulting (leaving as Engagement Manager) and later at Prescient Advisory, where I helped build an advisory team within the Prescient Healthcare Group.

Before consulting, I worked at Harvard University's Wyss Institute (Disease Biophysics Group), where I helped develop microphysiological chip-based platforms to model functional and diseased organ states and support drug development for complex diseases. I had the opportunity to patent this technology and navigate an out-licensing agreement through an appointment with Harvard's Office of Technology Development. Earlier experiences include LifeNet Health, Carnegie Mellon University, and the University of Toronto.

Outside of work, I enjoy playing golf and tennis, cycling around San Francisco, and family trips to state and national parks.

Portfolio

All / Insights / Journal / Review / Book Chapter / Conference

Kfoury, J., Shrivats, A.R., Robertson, S., Grabenstatter, K. (2017) The New Normal for Biopharma as Price Growth Finally Slows. L.E.K. Insights.
Shrivats, A.R., McDermott, M.C., Klimak, M., Averick, S., Pan, H., Matyjaszewski, M., Mishina, Y., Hollinger, J.O. (2015) Nanogel-mediated RNAi Against Runx2 and Osx Inhibits Osteogenic Differentiation in Constitutively Active BMPR1A Osteoblasts. ACS Biomaterials Science and Engineering.
Shrivats, A.R., Mishina, Y., Averick, S., Matyjaszewski, M., Hollinger, J.O. (2015) In Vivo GFP Knockdown by Cationic Nanogel-siRNA Polyplexes. Bioengineering 2 (3), 160-175.
Shrivats, A.R., Mackenzie, M.C., Konkolewicz, D., Averick, S.E., McDermott, M.C., Hollinger, J.O. Matyjaszewski, K. (2015) Synthesis of Poly(meth)acrylates with Thioether and Tertiary Sulfonium Groups by ARGET ATRP and their use as siRNA Delivery Agents. Biomacromolecules 16 (1), 236-245.
Shrivats, A.R. (2014). Inhibition of Osteogenic Differentiation by Nanogel-Mediated siRNA Delivery. FOP Drug Development Forum (Boston, Massachusetts). November 20th, 2014. Podium.
Shrivats, A.R., Hsu, E., Averick, S., Klimak, M., Watt, A.C.S., DeMaio, M., Matyjaszewski, K., Hollinger, J.O. (2014) Cationic Nanogel-mediated Runx2 and Osterix siRNA Delivery Decreases Mineralization in MC3T3 Cells. Clinical Orthopaedics and Related Research.
Shrivats, A.R., McDermott M.C., Hollinger, J.O. (2014) Bone Tissue Engineering: State of the Union. Drug Discovery Today 19 (6), 781-786.
Shrivats, A.R., and Hollinger, J.O. (2014). The Delivery and Evaluation of RNAi Therapeutics for Heterotopic Ossification Pathologies. In Biomimetics and Stem Cells, Methods in Molecular Biology 1202, 149-160.
Shrivats, A.R., McDermott, M.C., Averick, S., Cho, H., McKenzie, M., Matyjaszewski, K., Mishina, Y., et al. (2014). RNA Interference Therapeutics For Fibrodysplasia Ossificans Progressiva. In Orthopaedic Research Society (New Orleans, Louisiana). March 18th, 2014. Podium.
Hsu, E.W., Liu, S., Shrivats, A.R., Watt, A.C.S., McBride,..., Matyjaszewski, K., and Hollinger, J.O. (2014). Cationic Nanostructured Polymers for siRNA Delivery in Murine Calvarial Pre-Osteoblasts. Journal of Biomedical Nanotechnology 10 (6), 1130-1136.
Shrivats, A.R., Liu, S., Watt, A., Hsu, E., Averick, S., Cho, H., Alvarez, P., McBride, S., Mishina, Y., et al. (2013). The Next Generation of Cationic Polymers for Gene Delivery. In Material Science and Technology (Montreal, Quebec). October 30th, 2013. Podium.
Hsu, E., Alvarez, P, Schutte, L, Donovan, A., Liu, S., Shrivats, A.R., Hollinger, J.O. (2013). Animal Models and Clinical Applications: Bone Regeneration. Biomaterials and Regenerative Medicine. Cambridge University Press. In press.
Shrivats, A.R., Hsu, E., Watt, A., McBride, S., Liu, S., Alvarez-Urena, P., Averick, S., Cho, H., Paredes, E., et al. (2013). The development of safe and effective polymeric carriers for siRNA delivery. In Society for Biomaterials (Boston, Massachusetts). April 13th, 2013. Podium.
Averick, S.E., Paredes, E., Irastorza, A., Shrivats, A.R., Srinivasan, A., Siegwart, D.J., Magenau, A.J., Cho, H.Y., Hsu, E., Averick, A.A., et al. (2012). Preparation of cationic nanogels for nucleic acid delivery. Biomacromolecules 13, 3445-3449.
Shrivats, A.R., Alvarez-Urena, P., Schutte, L., and Hollinger, J.O. (2012). Bone Regeneration. In Principles of Tissue Engineering, R. Lanza, R. Langer, and J.P. Vacanti, eds. In press.
Rauh, F., Dornish, M., Street, R., and Shrivats, A.R. (2011). Complex Polysaccharides: Chitosan and Alginate. In An Introduction to Biomaterials, Second Edition, J.O. Hollinger, ed. (CRC Press). In press.
Cho, H.Y., Srinivasan, A., Hong, J., Hsu, E., Liu, S., Shrivats, A., Kwak, D., Bohaty, A.K., Paik, H.J., Hollinger, J.O., et al. (2011). Synthesis of biocompatible PEG-Based star polymers with cationic and degradable core for siRNA delivery. Biomacromolecules 12, 3478-3486.
Srinivasan, A., Sriram, S., Watt, A., Hsu, E., Shrivats, A., Cho, H., Matyjaszewski, K., and Hollinger, J. (2010). Delivery of siRNA Using Cationic Nanostructured Star Polymers to Prevent Myoblast Cell Differentiation to Bone. In Tissue Engineering and Regenerative Medicine International Society (Orlando, Florida). Podium.

Arun R Shrivats, PhD

About Me

Portfolio

Connect